HUS Pharmacy, HUS Helsinki University Hospital, Helsinki, Finland.
Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
BMC Pediatr. 2023 Oct 31;23(1):548. doi: 10.1186/s12887-023-04333-2.
Paediatric patients are prone to medication errors, and only a few studies have explored errors in high-alert medications in children. The present study aimed to investigate the prevalence and nature of medication errors involving high-alert medications and whether high-alert medications are more likely associated with severe patient harm and higher error risk classification compared to other drugs.
This study was a cross-sectional report of self-reported medication errors in a paediatric university hospital in 2018-2020. Medication error reports involving high-alert medications were investigated by descriptive quantitative analysis to identify the prevalence of different drugs, Anatomical Therapeutic Chemical groups, administration routes, and the most severe medication errors. Crosstabulation and Pearson Chi-Square (χ2) tests were used to compare the likelihood of more severe consequences to the patient and higher error risk classification between medication errors involving high-alert medications and other drugs.
Among the reported errors (n = 2,132), approximately one-third (34.8%, n = 743) involved high-alert medications (n = 872). The most common Anatomical Therapeutic Chemical subgroups were blood substitutes and perfusion solutions (B05; n = 345/872, 40%), antineoplastic agents (L01; n = 139/872, 16%), and analgesics (N02; n = 98/872, 11%). The majority of high-alert medications were administered intravenously (n = 636/872, 73%). Moreover, IV preparations were administered via off-label routes (n = 52/872, 6%), such as oral, inhalation and intranasal routes. Any degree of harm (minor, moderate or severe) to the patient and the highest risk classifications (IV-V) were more likely to be associated with medication errors involving high-alert medications (n = 743) when compared to reports involving other drugs (n = 1,389).
Preventive risk management should be targeted on high-alert medications in paediatric hospital settings. In these actions, the use of intravenous drugs, such as parenteral nutrition, concentrated electrolytes, analgesics and antineoplastic agents, and off-label use of medications should be prioritised. Further research on the root causes of medication errors involving high-alert medications and the effectiveness of safeguards is warranted.
儿科患者容易发生用药错误,仅有少数研究探讨了儿童高警示药物的用药错误。本研究旨在调查高警示药物用药错误的发生率和性质,以及与其他药物相比,高警示药物是否更容易与严重的患者伤害和更高的错误风险分类相关。
这是一项 2018 年至 2020 年在一所儿科大学医院进行的用药错误横断面报告。通过描述性定量分析调查涉及高警示药物的用药错误报告,以确定不同药物、解剖治疗化学组、给药途径和最严重的用药错误的发生率。卡方检验(χ2)用于比较涉及高警示药物和其他药物的用药错误之间更严重的患者后果和更高的错误风险分类的可能性。
在所报告的错误(n=2132)中,约三分之一(34.8%,n=743)涉及高警示药物(n=872)。最常见的解剖治疗化学亚组是血液替代品和灌注溶液(B05;n=345/872,40%)、抗肿瘤药物(L01;n=139/872,16%)和镇痛药(N02;n=98/872,11%)。大多数高警示药物为静脉内给药(n=636/872,73%)。此外,静脉内制剂通过标签外途径(n=52/872,6%)给药,例如口服、吸入和鼻内途径。与报告涉及其他药物(n=1389)相比,任何程度的患者伤害(轻度、中度或重度)和最高风险分类(IV-V)更可能与涉及高警示药物的用药错误(n=743)相关。
在儿科医院环境中,应针对高警示药物进行预防性风险管理。在这些行动中,应优先考虑静脉内药物的使用,如肠外营养、浓缩电解质、镇痛药和抗肿瘤药物,以及药物的标签外使用。需要进一步研究高警示药物用药错误的根本原因和安全措施的有效性。